All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gleason score > 7 Gleason score ≤ 7 Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl LDH > ULN LDH ≤ULN metastasis (bone) metastasis (visceral)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
prostate cancer (PC), ipilimumab alone vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CA184-043, 2014 0.85 [0.72; 1.00]
CA184-095, 2017 1.11 [0.88; 1.40]
0.96 [0.74 ; 1.24 ] CA184-043, 2014, CA184-095, 2017 2 71% 1,401 low not evaluable progression or deaths (PFS)detailed results CA184-043, 2014 0.70 [0.60; 0.81]
CA184-095, 2017 0.67 [0.55; 0.81]
0.69 [0.61 ; 0.77 ] CA184-043, 2014, CA184-095, 2017 2 0% 1,401 low not evaluable AE (any grade)detailed results CA184-043, 2014 4.23 [1.92; 9.30]
CA184-095, 2017 1.98 [1.00; 3.93]
2.82 [1.34 ; 5.93 ] CA184-043, 2014, CA184-095, 2017 2 51% 1,387 low not evaluable AE (grade 3-4)detailed results CA184-043, 2014 2.08 [1.57; 2.76]
CA184-095, 2017 11.20 [5.91; 21.26]
4.71 [0.91 ; 24.49 ] CA184-043, 2014, CA184-095, 2017 2 95% 1,387 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CA184-043, 2014 2.88 [2.05; 4.06]
CA184-095, 2017 4.78 [2.89; 7.94]
3.58 [2.19 ; 5.86 ] CA184-043, 2014, CA184-095, 2017 2 62% 1,387 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CA184-095, 2017 4.60 [2.55; 8.28]
4.60 [2.55 ; 8.28 ] CA184-095, 2017 1 0% 598 NA not evaluable SAE (any grade)detailed results CA184-095, 2017 3.15 [2.18; 4.57]
3.15 [2.18 ; 4.57 ] CA184-095, 2017 1 0% 598 NA not evaluable SAE (grade 3-4)detailed results CA184-095, 2017 2.55 [1.70; 3.82]
2.55 [1.70 ; 3.82 ] CA184-095, 2017 1 0% 598 NA not evaluable STRAE (grade 3-4)detailed results CA184-095, 2017 17.86 [6.48; 49.27]
17.86 [6.48 ; 49.27 ] CA184-095, 2017 1 0% 598 NA not evaluable TRAE (any grade)detailed results CA184-043, 2014 3.61 [2.67; 4.89]
CA184-095, 2017 14.03 [6.42; 30.66]
6.77 [1.80 ; 25.50 ] CA184-043, 2014, CA184-095, 2017 2 90% 1,387 low not evaluable TRAE (grade 3-4)detailed results CA184-043, 2014 5.04 [3.42; 7.41]
5.04 [3.42 ; 7.41 ] CA184-043, 2014 1 0% 789 NA not evaluable TRAE leading to death (grade 5)detailed results CA184-095, 2017 9.16 [0.53; 158.85]
9.16 [0.53 ; 158.85 ] CA184-095, 2017 1 0% 598 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CA184-043, 2014 2.88 [2.05; 4.06]
2.88 [2.05 ; 4.06 ] CA184-043, 2014 1 0% 789 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CA184-043, 2014 3.70 [2.43; 5.65]
3.70 [2.43 ; 5.65 ] CA184-043, 2014 1 0% 789 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.18; 22.37]
2.02 [0.18 ; 22.37 ] CA184-043, 2014 1 0% 789 NA not evaluable Colitis TRAE (grade 3-4)detailed results Out of scale CA184-043, 2014 37.97 [2.28; 632.95]
37.97 [2.28 ; 632.95 ] CA184-043, 2014 1 0% 789 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CA184-095, 2017 5.04 [0.27; 92.68]
5.04 [0.27 ; 92.68 ] CA184-095, 2017 1 0% 598 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Out of scale CA184-043, 2014 23.14 [7.19; 74.50]
CA184-095, 2017 68.89 [4.24; 1120.59]
27.24 [9.27 ; 80.07 ] CA184-043, 2014, CA184-095, 2017 2 0% 1,387 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CA184-043, 2014 3.05 [0.61; 15.23]
3.05 [0.61 ; 15.23 ] CA184-043, 2014 1 0% 789 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CA184-095, 2017 2.53 [0.55; 11.67]
2.53 [0.55 ; 11.67 ] CA184-095, 2017 1 0% 598 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Out of scale CA184-043, 2014 28.89 [9.01; 92.57]
28.89 [9.01 ; 92.57 ] CA184-043, 2014 1 0% 789 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CA184-043, 2014 10.19 [0.55; 187.21]
10.19 [0.55 ; 187.21 ] CA184-043, 2014 1 0% 789 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CA184-043, 2014 4.05 [0.18; 90.01]
4.05 [0.18 ; 90.01 ] CA184-043, 2014 1 0% 789 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CA184-043, 2014 2.30 [0.70; 7.52]
2.30 [0.70 ; 7.52 ] CA184-043, 2014 1 0% 789 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CA184-043, 2014 2.03 [0.50; 8.18]
2.03 [0.50 ; 8.18 ] CA184-043, 2014 1 0% 789 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CA184-043, 2014 0.50 [0.05; 5.57]
0.50 [0.05 ; 5.57 ] CA184-043, 2014 1 0% 789 NA not evaluable Nausea TRAE (grade 3-4)detailed results CA184-095, 2017 7.09 [0.40; 125.56]
7.09 [0.40 ; 125.56 ] CA184-095, 2017 1 0% 598 NA not evaluable Neurologic TRAE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
CA184-095, 2017 0.50 [0.03; 8.00]
0.87 [0.10 ; 7.48 ] CA184-043, 2014, CA184-095, 2017 2 0% 1,387 low not evaluable Rash TRAE (grade 3-4)detailed results CA184-043, 2014 4.05 [0.18; 90.01]
CA184-095, 2017 10.21 [0.59; 175.63]
6.69 [0.82 ; 54.44 ] CA184-043, 2014, CA184-095, 2017 2 0% 1,387 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CA184-043, 2014 8.13 [0.43; 154.37]
8.13 [0.43 ; 154.37 ] CA184-043, 2014 1 0% 789 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CA184-095, 2017 4.02 [0.21; 76.42]
4.02 [0.21 ; 76.42 ] CA184-095, 2017 1 0% 598 NA not evaluable Abdominal pain AE (grade 3-4)detailed results CA184-043, 2014 0.86 [0.29; 2.59]
0.86 [0.29 ; 2.59 ] CA184-043, 2014 1 0% 789 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results CA184-043, 2014 3.57 [0.74; 17.31]
3.57 [0.74 ; 17.31 ] CA184-043, 2014 1 0% 789 NA not evaluable Adrenal insufficiency AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.18; 22.37]
2.02 [0.18 ; 22.37 ] CA184-043, 2014 1 0% 789 NA not evaluable Anaemia AE (grade 3-4)detailed results CA184-043, 2014 0.93 [0.59; 1.47]
0.93 [0.59 ; 1.47 ] CA184-043, 2014 1 0% 789 NA not evaluable Arthralgia AE (grade 3-4)detailed results CA184-043, 2014 0.86 [0.29; 2.59]
0.86 [0.29 ; 2.59 ] CA184-043, 2014 1 0% 789 NA not evaluable Asthenia AE (grade 3-4)detailed results CA184-043, 2014 2.09 [1.06; 4.12]
2.09 [1.06 ; 4.12 ] CA184-043, 2014 1 0% 789 NA not evaluable Back pain AE (grade 3-4)detailed results CA184-043, 2014 0.69 [0.35; 1.40]
0.69 [0.35 ; 1.40 ] CA184-043, 2014 1 0% 789 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results CA184-043, 2014 0.83 [0.54; 1.28]
0.83 [0.54 ; 1.28 ] CA184-043, 2014 1 0% 789 NA not evaluable Cardiac disorders AE (grade 3-4)detailed results CA184-043, 2014 4.13 [1.16; 14.74]
4.13 [1.16 ; 14.74 ] CA184-043, 2014 1 0% 789 NA not evaluable Colitis AE (grade 3-4)detailed results Out of scale CA184-043, 2014 37.97 [2.28; 632.95]
37.97 [2.28 ; 632.95 ] CA184-043, 2014 1 0% 789 NA not evaluable Constipation AE (grade 3-4)detailed results CA184-043, 2014 0.67 [0.11; 4.03]
0.67 [0.11 ; 4.03 ] CA184-043, 2014 1 0% 789 NA not evaluable Cough AE (grade 3-4)detailed results CA184-043, 2014 4.05 [0.18; 90.01]
4.05 [0.18 ; 90.01 ] CA184-043, 2014 1 0% 789 NA not evaluable Decreased appetite AE (grade 3-4)detailed results CA184-043, 2014 1.27 [0.59; 2.75]
1.27 [0.59 ; 2.75 ] CA184-043, 2014 1 0% 789 NA not evaluable Diabetes mellitus AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CA184-043, 2014 10.81 [4.89; 23.91]
10.81 [4.89 ; 23.91 ] CA184-043, 2014 1 0% 789 NA not evaluable Dizziness AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.06; 16.17]
1.01 [0.06 ; 16.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CA184-043, 2014 2.67 [1.10; 6.46]
2.67 [1.10 ; 6.46 ] CA184-043, 2014 1 0% 789 NA not evaluable Endocrine disorders AE (grade 3-4)detailed results CA184-043, 2014 3.05 [0.61; 15.23]
3.05 [0.61 ; 15.23 ] CA184-043, 2014 1 0% 789 NA not evaluable Epistaxis AE (grade 3-4)detailed results CA184-043, 2014 0.50 [0.02; 15.04]
0.50 [0.02 ; 15.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Erythema AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Eye disorders AE (grade 3-4)detailed results CA184-043, 2014 0.60 [0.14; 2.53]
0.60 [0.14 ; 2.53 ] CA184-043, 2014 1 0% 789 NA not evaluable Fatigue AE (grade 3-4)detailed results CA184-043, 2014 1.17 [0.73; 1.88]
1.17 [0.73 ; 1.88 ] CA184-043, 2014 1 0% 789 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.06; 16.17]
1.01 [0.06 ; 16.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Gastritis AE (grade 3-4)detailed results CA184-043, 2014 8.13 [0.43; 154.37]
8.13 [0.43 ; 154.37 ] CA184-043, 2014 1 0% 789 NA not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results CA184-043, 2014 3.31 [2.16; 5.08]
3.31 [2.16 ; 5.08 ] CA184-043, 2014 1 0% 789 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results CA184-043, 2014 1.26 [0.89; 1.79]
1.26 [0.89 ; 1.79 ] CA184-043, 2014 1 0% 789 NA not evaluable Headache AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.14; 7.19]
1.01 [0.14 ; 7.19 ] CA184-043, 2014 1 0% 789 NA not evaluable Hepatobiliary disorders (AE grade 3-4)detailed results CA184-043, 2014 7.16 [0.88; 58.50]
7.16 [0.88 ; 58.50 ] CA184-043, 2014 1 0% 789 NA not evaluable Hypertension AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.06; 16.17]
1.01 [0.06 ; 16.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Hypophysitis AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.06; 16.17]
1.01 [0.06 ; 16.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results CA184-043, 2014 4.05 [0.18; 90.01]
4.05 [0.18 ; 90.01 ] CA184-043, 2014 1 0% 789 NA not evaluable Increase AST AE (grade 3-4)detailed results CA184-043, 2014 14.59 [1.91; 111.51]
14.59 [1.91 ; 111.51 ] CA184-043, 2014 1 0% 789 NA not evaluable Increased ALT AE (grade 3-4)detailed results CA184-043, 2014 3.07 [0.82; 11.43]
3.07 [0.82 ; 11.43 ] CA184-043, 2014 1 0% 789 NA not evaluable Infections and infestations AE (grade 3-4)detailed results CA184-043, 2014 2.13 [1.22; 3.71]
2.13 [1.22 ; 3.71 ] CA184-043, 2014 1 0% 789 NA not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results CA184-043, 2014 2.56 [0.80; 8.23]
2.56 [0.80 ; 8.23 ] CA184-043, 2014 1 0% 789 NA not evaluable Investigations AE (grade 3-4)detailed results CA184-043, 2014 1.82 [1.17; 2.84]
1.82 [1.17 ; 2.84 ] CA184-043, 2014 1 0% 789 NA not evaluable Leucopenia AE (grade 3-4)detailed results CA184-043, 2014 0.33 [0.03; 3.23]
0.33 [0.03 ; 3.23 ] CA184-043, 2014 1 0% 789 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results CA184-043, 2014 1.88 [1.18; 2.99]
1.88 [1.18 ; 2.99 ] CA184-043, 2014 1 0% 789 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Musculoskeletal and connective tissue disorders AE (grade 3-4)detailed results CA184-043, 2014 0.68 [0.44; 1.04]
0.68 [0.44 ; 1.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Myalgia AE (grade 3-4)detailed results CA184-043, 2014 3.04 [0.31; 29.34]
3.04 [0.31 ; 29.34 ] CA184-043, 2014 1 0% 789 NA not evaluable Myopathy AE (grade 3-4)detailed results CA184-043, 2014 0.50 [0.02; 15.04]
0.50 [0.02 ; 15.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Nausea AE (grade 3-4)detailed results CA184-043, 2014 1.60 [0.61; 4.17]
1.60 [0.61 ; 4.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Nervous system disorders AE (grade 3-4)detailed results CA184-043, 2014 0.83 [0.49; 1.43]
0.83 [0.49 ; 1.43 ] CA184-043, 2014 1 0% 789 NA not evaluable Neutropenia AE (grade 3-4)detailed results CA184-043, 2014 0.17 [0.01; 3.34]
0.17 [0.01 ; 3.34 ] CA184-043, 2014 1 0% 789 NA not evaluable Paraesthesia AE (grade 3-4)detailed results CA184-043, 2014 1.01 [0.06; 16.17]
1.01 [0.06 ; 16.17 ] CA184-043, 2014 1 0% 789 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results CA184-043, 2014 0.50 [0.02; 15.04]
0.50 [0.02 ; 15.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results CA184-043, 2014 0.25 [0.01; 5.58]
0.25 [0.01 ; 5.58 ] CA184-043, 2014 1 0% 789 NA not evaluable Pneumonia AE (grade 3-4)detailed results CA184-043, 2014 4.13 [1.16; 14.74]
4.13 [1.16 ; 14.74 ] CA184-043, 2014 1 0% 789 NA not evaluable Pneumonitis AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Proteinuria AE (grade 3-4)detailed results CA184-043, 2014 0.50 [0.02; 15.04]
0.50 [0.02 ; 15.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Pruritus AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Pyrexia AE (grade 3-4)detailed results CA184-043, 2014 5.09 [0.59; 43.77]
5.09 [0.59 ; 43.77 ] CA184-043, 2014 1 0% 789 NA not evaluable Rash AE (grade 3-4)detailed results CA184-043, 2014 4.05 [0.18; 90.01]
4.05 [0.18 ; 90.01 ] CA184-043, 2014 1 0% 789 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results CA184-043, 2014 1.11 [0.60; 2.04]
1.11 [0.60 ; 2.04 ] CA184-043, 2014 1 0% 789 NA not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results CA184-043, 2014 1.68 [0.89; 3.19]
1.68 [0.89 ; 3.19 ] CA184-043, 2014 1 0% 789 NA not evaluable Sepsis AE (grade 3-4)detailed results CA184-043, 2014 1.52 [0.25; 9.12]
1.52 [0.25 ; 9.12 ] CA184-043, 2014 1 0% 789 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results CA184-043, 2014 12.26 [0.68; 220.32]
12.26 [0.68 ; 220.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results CA184-043, 2014 0.37 [0.10; 1.42]
0.37 [0.10 ; 1.42 ] CA184-043, 2014 1 0% 789 NA not evaluable Urticaria AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Uveitis AE (grade 3-4)detailed results CA184-043, 2014 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CA184-043, 2014 1 0% 789 NA not evaluable Vascular disorders AE (grade 3-4)detailed results CA184-043, 2014 1.45 [0.55; 3.85]
1.45 [0.55 ; 3.85 ] CA184-043, 2014 1 0% 789 NA not evaluable Vomiting AE (grade 3-4)detailed results CA184-043, 2014 0.78 [0.29; 2.11]
0.78 [0.29 ; 2.11 ] CA184-043, 2014 1 0% 789 NA not evaluable Weight decreased AE (grade 3-4)detailed results CA184-043, 2014 5.09 [0.59; 43.77]
5.09 [0.59 ; 43.77 ] CA184-043, 2014 1 0% 789 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 21:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 12,206,207,208,332
- treatments: 329,558